A Look Back At June In Biotech

As of the end of Q2, 2004, 11 companies posted year-to-date gains in excess of 100%. Two companies topped 200% so far. The leader of the pack is Elan (ELN) with a gain of 259%, followed closely by Pharmion (PHRM), up 221%. Rounding out the 100%+ gainers are Keryx (KERX), Valentis (VLTS), ConjuChem (CJC.TO), Sepracor (SEPR), OSI (OSIP), ImClone (IMCL), Northfield (NFLD), MorphoSys (MPHSF.PK) and Eyetech (EYET). This year's biggest losers are BioVeris (BIOV), -55% and Myogen (MYOG), -46% followed by NeoPharm (NEOL), Pharmacopeia (PCOP), SuperGen (SUPG), Exact (EXAS), Adolor (ADLR), and CipherGen (CIPH).